Zhao Min, Calabretta Raffaella, Yu Josef, Binder Patrick, Hu Shuo, Hacker Marcus, Li Xiang
Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, Floor 3L, 1090 Vienna, Austria.
Biology (Basel). 2022 Sep 24;11(10):1395. doi: 10.3390/biology11101395.
Cardiac amyloidosis (CA) is a heterogeneous group of diseases in which extracellular insoluble amyloid proteins are deposited in specific organs and tissues locally or systemically, thereby interfering with physiological function. Transthyretin protein (TTR) and light chain (AL) amyloidosis are the most common types of cardiac amyloidosis. Radionuclide bone scintigraphy has recently become the most common non-invasive test for the diagnosis of TTR-CA but is of limited value for the diagnosis of AL-CA. PET has proved promising for the diagnosis of CA and its applications are expected to expand in the future. This review summarizes the current bone scintigraphy and amyloid-targeting Positron emission tomography (PET) imaging, the binding imaging properties of radiotracers, and the values of diagnosis, prognosis, and monitoring therapy response in CA.
心脏淀粉样变性（CA）是一组异质性疾病，其中细胞外不溶性淀粉样蛋白局部或全身沉积在特定器官和组织中，从而干扰生理功能。转甲状腺素蛋白（TTR）和轻链（AL）淀粉样变性是心脏淀粉样变性最常见的类型。放射性核素骨闪烁显像最近已成为诊断TTR-CA最常用的非侵入性检查，但对AL-CA的诊断价值有限。PET已被证明在CA的诊断中很有前景，其应用有望在未来得到扩展。本综述总结了目前的骨闪烁显像和淀粉样蛋白靶向正电子发射断层扫描（PET）成像、放射性示踪剂的结合成像特性以及CA在诊断、预后和监测治疗反应方面的价值。
